東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Antiviral and antitumor functions of...

Li, Geqiang.

FindBook

Google Book

Amazon

博客來

Antiviral and antitumor functions of RNase L.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Antiviral and antitumor functions of RNase L./
作者:	Li, Geqiang.
面頁冊數:	151 p.
附註:	Source: Dissertation Abstracts International, Volume: 65-07, Section: B, page: 3308.
Contained By:	Dissertation Abstracts International65-07B.
標題:	Biology, Molecular. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3141157
ISBN:	0496882910

Antiviral and antitumor functions of RNase L.
Li, Geqiang.

Antiviral and antitumor functions of RNase L. - 151 p.

Source: Dissertation Abstracts International, Volume: 65-07, Section: B, page: 3308.

Thesis (Ph.D.)--Case Western Reserve University, 2005.

RNase L is an endoribonuclease that functions in the molecular pathways of interferon (IFN) action against viral infections. Although the pro-apoptotic activity of RNase L is well known, how RNase L activation during viral infection leads to apoptosis is not clear. Recently, RNase L was considered to be a tumor suppressor based on its pro-apoptotic activity and mapping to hereditary prostate cancer allele 1 (HPC1). While involvement of a viral pathogen in prostate cancer was proposed (Silverman 2003), the unknown novel mechanism of RNase L in the suppression of prostate cancer progression still remains possible. Several lines of evidence implied that RNase L may possess an unidentified function: first, RNase L+/+ fibroblasts are different from RNase L-/- in morphology. Second, RNase L -/- mice showed a 5-day delayed rejection of skin allograft and a dramatic reduction in inflammatory infiltrates (Silverman RH et al 2002), indicating that RNase L play a role in immunosystem. Third, RNase L was found to interact with actin cytoskeleton (Tnani M et al 1998), and the interactions were abolished by PMA treatment of the cells. Finally, three inactivating mutations (M1I, E265X, and Delta157) and an additional nine missense variants (G59S, I97L, I220V, V247M, G296V, and S322F) in RNase L have been observed in prostate cancer cases. No mutation is mapped in the ribonuclease domain, indicating that ribonuclease domain might not be involved in RNtase L related pathogenesis in prostate cancer. My thesis thus focused the possible mechanisms of the antiviral and antitumor functions of RNase L.

ISBN: 0496882910Subjects--Topical Terms:

1017719
Biology, Molecular.

Antiviral and antitumor functions of RNase L.
LDR:03355nmm 2200301 4500 001 1812655
005 20060427132621.5
008 130610s2005 eng d
020 $a 0496882910
035 $a (UnM)AAI3141157
035 $a AAI3141157
040 $a UnM $c UnM
100 1 $a Li, Geqiang. $3 1902198
245 1 0 $a Antiviral and antitumor functions of RNase L.
300 $a 151 p.
500 $a Source: Dissertation Abstracts International, Volume: 65-07, Section: B, page: 3308.
500 $a Adviser: Robert H. Silverman.
502 $a Thesis (Ph.D.)--Case Western Reserve University, 2005.
520 $a RNase L is an endoribonuclease that functions in the molecular pathways of interferon (IFN) action against viral infections. Although the pro-apoptotic activity of RNase L is well known, how RNase L activation during viral infection leads to apoptosis is not clear. Recently, RNase L was considered to be a tumor suppressor based on its pro-apoptotic activity and mapping to hereditary prostate cancer allele 1 (HPC1). While involvement of a viral pathogen in prostate cancer was proposed (Silverman 2003), the unknown novel mechanism of RNase L in the suppression of prostate cancer progression still remains possible. Several lines of evidence implied that RNase L may possess an unidentified function: first, RNase L+/+ fibroblasts are different from RNase L-/- in morphology. Second, RNase L -/- mice showed a 5-day delayed rejection of skin allograft and a dramatic reduction in inflammatory infiltrates (Silverman RH et al 2002), indicating that RNase L play a role in immunosystem. Third, RNase L was found to interact with actin cytoskeleton (Tnani M et al 1998), and the interactions were abolished by PMA treatment of the cells. Finally, three inactivating mutations (M1I, E265X, and Delta157) and an additional nine missense variants (G59S, I97L, I220V, V247M, G296V, and S322F) in RNase L have been observed in prostate cancer cases. No mutation is mapped in the ribonuclease domain, indicating that ribonuclease domain might not be involved in RNtase L related pathogenesis in prostate cancer. My thesis thus focused the possible mechanisms of the antiviral and antitumor functions of RNase L.
520 $a In antiviral studies, my thesis showed that 2--5A, dsRNA and viral infection induced activation of the c-Jun NH2-terminal kinases (JNK) family of MAP kinases and viral induction of apoptosis are deficient in mouse cells lacking RNase L. In addition, 2--5A resulted in specific ribosomal RNA cleavage products coinciding with JNK activation. Moreover, 2--5A induced apoptosis was dramatically enhanced by IFN pretreatment in JNK1+/+ JNK2+/+ cells but not in Jnk1-/- Jnk2-/- cells. These findings suggest that JNK and RNase L function in an integrated signaling pathway during the IFN response that leads to elimination of virus-infected cells through apoptosis.
520 $a In antitumor studies, my research established that haptotaxis of RNase L-/- MEF cells increased about two fold, compared to their wildtype counterparts. (Abstract shortened by UMI.)
590 $a School code: 0042.
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0307
690 $a 0992
710 2 0 $a Case Western Reserve University. $3 1017714
773 0 $t Dissertation Abstracts International $g 65-07B.
790 1 0 $a Silverman, Robert H., $e advisor
790 $a 0042
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3141157